Sponsored Content Archives - Page 90 of 143 - BioProcess InternationalBioProcess International

Advancing the MAb Therapies of Tomorrow

Thomas Page (vice president, engineering and asset development, Fujifilm Diosynth Biotechnologies USA) 1:00–1:20 pm Page introduced Fujifilm Diosynth’s Saturn monoclonal antibody (MAb) platform, which is based on the Apollo cell line. A senior team working from three facilities designed this new platform by challenging everything from previous designs, keeping the best aspects, and throwing out what did not work well — while innovating where necessary. All functional units were represented and empowered to make decisions. The team used risk-based tools…

Panel Discussion: How CMO Business Models Have Adapted to Meet the Challenges and Opportunities of Protein-Based and Emerging Therapy Markets

by Alison Center

On Tuesday, 20 June 2017, BioProcess International presented a panel discussion from 1:20 to 2:00 pm as part of the “Emerging Therapies” session of its BPI Theater at the BIO annual convention in San Diego. Moderated by Gil Roth (president of the Pharma and Biopharma Outsourcing Association), the panel comprised John Foy (vice president of business management for biologics at Patheon), Michael A. Riley (vice president and general manager of Catalent Biologics), Victor Vinci (vice president and chief scientific officer…

Panel Discussion: Cell, Gene, and Tissue Therapies — Applying Key Lessons from the Evolution and Commercialization of Protein-Based Therapies

by Alison Center

On Tuesday, 20 June 2017, BioProcess International presented a panel discussion from 2:20 to 3:30 pm as part of the “Emerging Therapies” session of its BPI Theater at the BIO annual convention in San Diego. Moderated by David Brindley (University of Oxford and Harvard University), the panel comprised Morrie Ruffin (managing partner of the Alliance for Regenerative Medicine), David Backer (head of commercial development for gene editing and novel modalities at MilliporeSigma), Robert Preti (president and chief executive officer of…

Panel Discussion: Process and Business Considerations for Innovation — Supplier and End-User Perspectives

by Alison Center

On Wednesday, 21 June 2017, BioProcess International presented a panel discussion from 11:00 am to 12:00 pm as part of the “Emerging Techniques and Technologies” session of its BPI Theater at the BIO annual convention in San Diego. Moderated by Tom Ransohoff (vice president of BioProcess Technology Consultants), the panel comprised Stewart McNaull (senior vice president of business development at KBI Biopharma), Bernard Huyghe (senior director at Pfizer), John Bonham-Carter (director at Repligen, not pictured), and Todd J. Menkhaus (cofounder of…

Panel Discussion: Single-Use and Process Development Technologies — Making the Right Choices for Your Process

by Alison Center

At noon on Wednesday, 21 June 2017, BioProcess International presented a panel discussion as part of the “Emerging Techniques and Technologies” session of its BPI Theater at the BIO annual convention in San Diego. Moderated by Susan Dexter (managing director of Latham Biopharm Group), this panel comprised Deborah Harris (vice president of operations at Abzena), Magnus Schroeder (director of downstream process development at CMC Biologics), and Stephen Lam (vice president of operations at Patheon). There is no debate: Single-use technologies…

Panel Discussion: How to Differentiate Your Vaccine Platform in a Competitive Market

by Alison Center

On Wednesday, 21 June 2017, BioProcess International presented a panel discussion from 1:20 to 2:30 pm as part of the “Emerging Techniques and Technologies” session of its BPI Theater at the BIO annual convention in San Diego. Moderated by Joshua Speidel (managing director of the commercial practice team at Latham Biopharm Group), this panel comprised Diane Retallack (senior director of upstream processing and intellectual property at Pfenex), Rachel Felberbaum (senior director of business development at Protein Sciences Corporation), and William Taylor…

Routinely Identify Low-Level Attributes – Fast and Accurately

by BPI Contributor

This webcast features: Sibylle Heidelberger, Technical Marketing Manager for Biologics, SCIEX. Biotherapeutic peptide mapping LC-MS acquisition methods can make it difficult to routinely identify low-level modifications, such as deamidation and oxidation. This webinar discusses how the use of generic SWATH® Acquisition method on the benchtop X500B QTOF System and BioPharmaView™ Software allows you to confirm the identity of low-level attributes with fast and accurate batch analysis and processing. She also presents how the use of this unbiased data-independent SWATH® Acquisition…

Collaborate to Innovate: A Webinar Series

by BPI Contributor

As a senior leader in pharmaceutical development and manufacturing, you know that keeping up-to-date on industry trends is critical to maintaining competitive edge. But do you know how to actively drive these trends and apply them to your manufacturing processes? Are you collaborating with the right stakeholders in order to expand your capabilities and bring your innovation strategy to life? In this webinar series, three subject matter experts will share their perspective on the future of the industry and provide…

Buffer Selection in Biologics Manufacturing

by BPI Contributor

They’re far less exciting than the life-changing treatments they help create, but buffers play a critical role in upstream and downstream biomanufacturing processes. ANGUS takes you backstage with “Buffers in Biologics Manufacturing” – an in-depth article co-authored by Dr. Dave Green, Vice President of R&D, ANGUS, that explores the important variables to consider when selecting the right buffer (and buffer supplier). And, when it comes to biomanufacturing, we know a thing or two about buffers. Why? Because we invented them.…

Insulin Improves Cell Growth and Influenza Yield in a HEK293 Suspension Cell Line

by BPI Contributor

This webcast features: Aziza Manceur, Research Officer, National Research Council Canada To produce large quantities of vaccines in a rapid and cost-effective way is the main challenge that the vaccine industry is facing. Major changes to current bioprocesses are difficult to implement due to costs associated with the regulatory approval process. Therefore, we propose to use insulin, a protein currently used and approved in several processes and production platforms, as an additive to boost cell growth and viral production. The HEK293SF-3F6 cell…